Clinical Trial: Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07233720) titled 'Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma' on July 08.

Brief Summary: This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).

Study Start Date: Nov. 18

Study Type: OBSERVATIONAL

Condition: Marginal Zone Lymphoma

Intervention: DRUG: Zanubrutinib

160mg twice daily continuous oral administration.

DRUG: Rituximab

375mg/m2, Intravenous administration on day 1 of each 3-week cycle

Recruitment Status: RECRUITING

Sp...